Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac<sup>®</sup> and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study
Background: Vaccines that prevent SARS-CoV-2 infection are considered the most promising approach to modulating the pandemic. There is scarce evidence on the efficacy and safety of different vaccine prime-boost combinations in MHD patients since most clinical trials have used homologous mRNA vaccine...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/11/4/715 |
| _version_ | 1797603275506188288 |
|---|---|
| author | Phoom Narongkiatikhun Kajohnsak Noppakun Romanee Chaiwarith Poramed Winichakoon Surachet Vongsanim Yuttitham Suteeka Karn Pongsuwan Prit Kusirisin Nuttanun Wongsarikan Kanda Fanhchaksai Chantana Khamwan Dararat Dankai Vuddhidej Ophascharoensuk |
| author_facet | Phoom Narongkiatikhun Kajohnsak Noppakun Romanee Chaiwarith Poramed Winichakoon Surachet Vongsanim Yuttitham Suteeka Karn Pongsuwan Prit Kusirisin Nuttanun Wongsarikan Kanda Fanhchaksai Chantana Khamwan Dararat Dankai Vuddhidej Ophascharoensuk |
| author_sort | Phoom Narongkiatikhun |
| collection | DOAJ |
| description | Background: Vaccines that prevent SARS-CoV-2 infection are considered the most promising approach to modulating the pandemic. There is scarce evidence on the efficacy and safety of different vaccine prime-boost combinations in MHD patients since most clinical trials have used homologous mRNA vaccine regimens. Methods: This prospective observational study assessed the immunogenicity and safety of homologous CoronaVac<sup>®</sup> (SV-SV), ChAdOx1 nCoV-19 (AZD1222) (AZ-AZ), and the heterologous prime-boost of SV-AZ, among MHD patients. Results: A total of 130 MHD participants were recruited. On day 28, after the second dose, seroconversion results of the surrogate virus neutralization test were not different between vaccine regimens. The magnitude of the receptor-binding domain-specific IgG was highest among the SV-AZ. Different vaccine regimens had a distinct impact on seroconversion, for which the heterologous vaccine regimen demonstrated a higher probability of seroconversion (OR 10.12; <i>p</i> = 0.020, and OR 1.81; <i>p</i> = 0.437 for SV-AZ vs. SV-SV, and SV-AZ vs. AZ-AZ, respectively). There were no serious adverse events reported in any of the vaccine groups. Conclusions: Immunization with SV-SV, AZ-AZ, and SV-AZ could generate humoral immunity without any serious adverse events among MHD patients. Using the heterologous vaccine prime-boost seemed to be more efficacious in terms of inducing immunogenicity. |
| first_indexed | 2024-03-11T04:27:53Z |
| format | Article |
| id | doaj.art-312472deea724cadb6217a56c05db25f |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-11T04:27:53Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-312472deea724cadb6217a56c05db25f2023-11-17T21:40:43ZengMDPI AGVaccines2076-393X2023-03-0111471510.3390/vaccines11040715Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac<sup>®</sup> and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort StudyPhoom Narongkiatikhun0Kajohnsak Noppakun1Romanee Chaiwarith2Poramed Winichakoon3Surachet Vongsanim4Yuttitham Suteeka5Karn Pongsuwan6Prit Kusirisin7Nuttanun Wongsarikan8Kanda Fanhchaksai9Chantana Khamwan10Dararat Dankai11Vuddhidej Ophascharoensuk12Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandDivision of Nephrology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandDivision of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandDivision of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandDivision of Nephrology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandDivision of Nephrology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandDivision of Nephrology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandDivision of Nephrology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandDepartment of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandDivision of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandImmunology Laboratory, Diagnostic Laboratory, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandImmunology Laboratory, Diagnostic Laboratory, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandDivision of Nephrology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, ThailandBackground: Vaccines that prevent SARS-CoV-2 infection are considered the most promising approach to modulating the pandemic. There is scarce evidence on the efficacy and safety of different vaccine prime-boost combinations in MHD patients since most clinical trials have used homologous mRNA vaccine regimens. Methods: This prospective observational study assessed the immunogenicity and safety of homologous CoronaVac<sup>®</sup> (SV-SV), ChAdOx1 nCoV-19 (AZD1222) (AZ-AZ), and the heterologous prime-boost of SV-AZ, among MHD patients. Results: A total of 130 MHD participants were recruited. On day 28, after the second dose, seroconversion results of the surrogate virus neutralization test were not different between vaccine regimens. The magnitude of the receptor-binding domain-specific IgG was highest among the SV-AZ. Different vaccine regimens had a distinct impact on seroconversion, for which the heterologous vaccine regimen demonstrated a higher probability of seroconversion (OR 10.12; <i>p</i> = 0.020, and OR 1.81; <i>p</i> = 0.437 for SV-AZ vs. SV-SV, and SV-AZ vs. AZ-AZ, respectively). There were no serious adverse events reported in any of the vaccine groups. Conclusions: Immunization with SV-SV, AZ-AZ, and SV-AZ could generate humoral immunity without any serious adverse events among MHD patients. Using the heterologous vaccine prime-boost seemed to be more efficacious in terms of inducing immunogenicity.https://www.mdpi.com/2076-393X/11/4/715COVID-19inactivated vaccinereplication-defective viral vectors vaccinevaccine immunogenicityhemodialysis |
| spellingShingle | Phoom Narongkiatikhun Kajohnsak Noppakun Romanee Chaiwarith Poramed Winichakoon Surachet Vongsanim Yuttitham Suteeka Karn Pongsuwan Prit Kusirisin Nuttanun Wongsarikan Kanda Fanhchaksai Chantana Khamwan Dararat Dankai Vuddhidej Ophascharoensuk Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac<sup>®</sup> and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study Vaccines COVID-19 inactivated vaccine replication-defective viral vectors vaccine vaccine immunogenicity hemodialysis |
| title | Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac<sup>®</sup> and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study |
| title_full | Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac<sup>®</sup> and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study |
| title_fullStr | Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac<sup>®</sup> and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study |
| title_full_unstemmed | Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac<sup>®</sup> and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study |
| title_short | Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac<sup>®</sup> and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study |
| title_sort | immunogenicity and safety of homologous and heterologous prime boost of coronavac sup r sup and chadox1 ncov 19 among hemodialysis patients an observational prospective cohort study |
| topic | COVID-19 inactivated vaccine replication-defective viral vectors vaccine vaccine immunogenicity hemodialysis |
| url | https://www.mdpi.com/2076-393X/11/4/715 |
| work_keys_str_mv | AT phoomnarongkiatikhun immunogenicityandsafetyofhomologousandheterologousprimeboostofcoronavacsupsupandchadox1ncov19amonghemodialysispatientsanobservationalprospectivecohortstudy AT kajohnsaknoppakun immunogenicityandsafetyofhomologousandheterologousprimeboostofcoronavacsupsupandchadox1ncov19amonghemodialysispatientsanobservationalprospectivecohortstudy AT romaneechaiwarith immunogenicityandsafetyofhomologousandheterologousprimeboostofcoronavacsupsupandchadox1ncov19amonghemodialysispatientsanobservationalprospectivecohortstudy AT poramedwinichakoon immunogenicityandsafetyofhomologousandheterologousprimeboostofcoronavacsupsupandchadox1ncov19amonghemodialysispatientsanobservationalprospectivecohortstudy AT surachetvongsanim immunogenicityandsafetyofhomologousandheterologousprimeboostofcoronavacsupsupandchadox1ncov19amonghemodialysispatientsanobservationalprospectivecohortstudy AT yuttithamsuteeka immunogenicityandsafetyofhomologousandheterologousprimeboostofcoronavacsupsupandchadox1ncov19amonghemodialysispatientsanobservationalprospectivecohortstudy AT karnpongsuwan immunogenicityandsafetyofhomologousandheterologousprimeboostofcoronavacsupsupandchadox1ncov19amonghemodialysispatientsanobservationalprospectivecohortstudy AT pritkusirisin immunogenicityandsafetyofhomologousandheterologousprimeboostofcoronavacsupsupandchadox1ncov19amonghemodialysispatientsanobservationalprospectivecohortstudy AT nuttanunwongsarikan immunogenicityandsafetyofhomologousandheterologousprimeboostofcoronavacsupsupandchadox1ncov19amonghemodialysispatientsanobservationalprospectivecohortstudy AT kandafanhchaksai immunogenicityandsafetyofhomologousandheterologousprimeboostofcoronavacsupsupandchadox1ncov19amonghemodialysispatientsanobservationalprospectivecohortstudy AT chantanakhamwan immunogenicityandsafetyofhomologousandheterologousprimeboostofcoronavacsupsupandchadox1ncov19amonghemodialysispatientsanobservationalprospectivecohortstudy AT dararatdankai immunogenicityandsafetyofhomologousandheterologousprimeboostofcoronavacsupsupandchadox1ncov19amonghemodialysispatientsanobservationalprospectivecohortstudy AT vuddhidejophascharoensuk immunogenicityandsafetyofhomologousandheterologousprimeboostofcoronavacsupsupandchadox1ncov19amonghemodialysispatientsanobservationalprospectivecohortstudy |